Volume | 309,984 |
|
|||||
News | - | ||||||
Day High | 0.4599 | Low High |
|||||
Day Low | 0.39 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
BiomX Inc | PHGE | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.45 | 0.39 | 0.4599 | 0.4446 | 0.479 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
667 | 309,984 | US$ 0.4256522 | US$ 131,945 | - | 0.1866 - 0.855 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
19:00:00 | 100 | US$ 0.4446 | USD |
BiomX Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
20.23M | 45.98M | - | 0 | -26.17M | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BiomX News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHGE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3465 | 0.499 | 0.3065 | 0.4261682 | 404,153 | 0.108 | 31.17% |
1 Month | 0.41 | 0.499 | 0.2675 | 0.374489 | 239,021 | 0.0445 | 10.85% |
3 Months | 0.2091 | 0.855 | 0.1866 | 0.6418297 | 2,840,530 | 0.2454 | 117.36% |
6 Months | 0.309 | 0.855 | 0.1866 | 0.615983 | 1,442,149 | 0.1455 | 47.09% |
1 Year | 0.30 | 0.855 | 0.1866 | 0.5991515 | 768,425 | 0.1545 | 51.50% |
3 Years | 6.76 | 6.85 | 0.132 | 0.6801888 | 358,213 | -6.31 | -93.28% |
5 Years | 10.65 | 11.05 | 0.132 | 0.9261881 | 246,728 | -10.20 | -95.73% |
BiomX Description
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. |